CROs offering Pathology & Histology Services with Biologics (Other)
8 published
8 published CROs match Pathology & Histology Services and Biologics (Other).
Locations in this set include United States, China, United Kingdom, Australia, Belgium, and Canada.
Capabilities that show up most often in this set: Preclinical In Vitro Studies, Preclinical In Vivo Studies, Biomarker Assays, In Vitro Pharmacology, and In Vivo Efficacy Models.
Matching companies
Champions OncologyLeading oncology CRO specializing in preclinical and clinical specialty testing, with over 1,400 patient-derived xenograft models, comprehensive multi-omic datasets, and proprietary platforms including flow cytometry, NGS, proteomics, and histopathology services.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Crown BiosciencePreclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
ITR LaboratoriesGLP-compliant nonclinical CRO specializing in safety and toxicology testing across in silico, in vitro, and in vivo modalities, with 35+ years of experience and nearly 6,000 completed studies.
InnoSer LaboratoriesPreclinical CRO offering GLP and non-GLP toxicology, custom genetically modified mouse models, and disease models across oncology, neurology, immunology, metabolic, and cardiovascular research. Supports programs from target discovery through IND-enabling studies.
LabcorpLabcorp is a global life sciences and healthcare company providing diagnostic testing, drug development, nonclinical research, central laboratory services, and real-world data solutions to healthcare providers, health systems, and biopharma companies.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/pathology-histology/biologics-other.md